Carfilzomib

Carfilzomib is a synthetic tetrapeptide epoxyketone and a second-generation proteasome inhibitor, recognized for its potent and selective action against the chymotrypsin-like activity of the 20S proteasome. Distinguished by its irreversible binding mechanism, Carfilzomib has become a valuable tool in biochemical and cellular research, particularly in studies focused on protein homeostasis and degradation pathways. Its unique structural features enable researchers to investigate the intricacies of ubiquitin-proteasome system (UPS) regulation, making it an indispensable compound for dissecting proteostasis networks. With high specificity and well-characterized mechanisms, Carfilzomib serves as a reference molecule for the development and comparison of novel proteasome-targeting agents in preclinical research contexts.

Proteasome Function Research: Carfilzomib is extensively employed in the exploration of proteasome structure and function within eukaryotic cells. By selectively inhibiting the 20S proteasome, it allows scientists to assess the consequences of impaired protein degradation on cellular processes, including cell cycle progression, apoptosis, and stress responses. Its use in these studies has advanced understanding of the critical role the proteasome plays in maintaining cellular protein quality control and has facilitated the identification of new regulatory proteins and pathways involved in proteostasis.

Cancer Biology Studies: In oncology research, this epoxyketone-based inhibitor is frequently utilized to model proteasome inhibition in tumor cells. By blocking proteasomal degradation of pro-apoptotic factors and cell cycle regulators, Carfilzomib induces cellular stress and apoptosis, providing a robust system for elucidating the molecular mechanisms underlying cancer cell sensitivity and resistance to proteasome inhibitors. Its application in these models supports the identification of biomarkers for proteasome inhibitor responsiveness and aids in the rational design of combination therapies targeting multiple proteolytic pathways.

Drug Discovery and Mechanistic Screening: As a benchmark compound, Carfilzomib is invaluable in high-throughput screening assays designed to identify novel proteasome inhibitors or compounds that modulate the UPS. Researchers leverage its well-characterized inhibitory profile to validate assay sensitivity and specificity, as well as to compare the efficacy and selectivity of new chemical entities. Its irreversible binding mode also provides insight into the structure-activity relationships governing proteasome inhibition, supporting the optimization of lead compounds in early-stage drug discovery programs.

Neurodegenerative Disease Models: The selective proteasome inhibition achieved by this compound is instrumental in modeling the protein aggregation and cellular dysfunction characteristic of neurodegenerative disorders such as Parkinson's, Alzheimer's, and Huntington's diseases. By disrupting UPS-mediated degradation of misfolded or aggregation-prone proteins, Carfilzomib enables researchers to mimic disease-relevant proteostasis imbalances in vitro and in vivo. These models are essential for unraveling the contributions of proteasome dysfunction to neurodegeneration and for evaluating candidate therapeutics targeting protein clearance pathways.

Immunological and Inflammatory Pathways: Carfilzomib's impact on antigen processing and presentation, as well as cytokine regulation, has made it a useful agent in immunology research. By inhibiting proteasomal degradation, it alters the repertoire of peptides presented by major histocompatibility complex (MHC) molecules, thereby influencing immune cell activation and response. Investigators utilize this property to dissect the interplay between proteasome function and immune signaling cascades, advancing knowledge of immune regulation and the development of novel immunomodulatory strategies.

Cellular Stress Response Analysis: In studies of cellular adaptation to proteotoxic and oxidative stress, Carfilzomib is deployed to probe the induction of compensatory pathways such as autophagy and the unfolded protein response (UPR). By selectively disrupting proteasome activity, it enables the examination of cross-talk between protein degradation systems and stress signaling networks. This application is pivotal for understanding how cells sense and respond to proteostasis challenges, informing strategies to modulate stress responses in various disease models. Through these diverse research applications, Carfilzomib remains a cornerstone molecule for advancing the molecular understanding of proteasome function and its implications in health and disease.

1. P-selectin and Complement’s Role in a Neonatal Model of Germinal Matrix Hemorrhage-Induced Secondary Injury

2. Adipose tissue is a key organ for the beneficial effects of GLP-2 metabolic function

3. Novel Peptide-Based PD1 Immunomodulators Demonstrate Efficacy in Infectious Disease Vaccines and Therapeutics

4. Cell-based adhesion assays for isolation of snake venom’s integrin antagonists

5. Effect of Probiotic Lactobacillus plantarum on Streptococcus mutans and Candida albicans Clinical Isolates from Children with Early Childhood Caries